Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Breast cancer subtypes: response to radiotherapy and potential radiosensitisation</title><author><name sortKey="Langlands, F E" sort="Langlands, F E" uniqKey="Langlands F" first="F E" last="Langlands">F E Langlands</name><affiliation><nlm:aff id="aff1"><addr-line>Section of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Leeds University, Leeds, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Horgan, K" sort="Horgan, K" uniqKey="Horgan K" first="K" last="Horgan">K. Horgan</name><affiliation><nlm:aff id="aff2"><addr-line>Department of Breast Surgery, Leeds General Infirmary, Leeds, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Dodwell, D D" sort="Dodwell, D D" uniqKey="Dodwell D" first="D D" last="Dodwell">D D Dodwell</name><affiliation><nlm:aff id="aff3"><addr-line>St James’s Institute of Oncology, St James Hospital, Leeds, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Smith, L" sort="Smith, L" uniqKey="Smith L" first="L" last="Smith">L. Smith</name><affiliation><nlm:aff id="aff1"><addr-line>Section of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Leeds University, Leeds, UK</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23392193</idno><idno type="pmc">3608055</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608055</idno><idno type="RBID">PMC:3608055</idno><idno type="doi">10.1259/bjr.20120601</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">004774</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004774</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Breast cancer subtypes: response to radiotherapy and potential radiosensitisation</title><author><name sortKey="Langlands, F E" sort="Langlands, F E" uniqKey="Langlands F" first="F E" last="Langlands">F E Langlands</name><affiliation><nlm:aff id="aff1"><addr-line>Section of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Leeds University, Leeds, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Horgan, K" sort="Horgan, K" uniqKey="Horgan K" first="K" last="Horgan">K. Horgan</name><affiliation><nlm:aff id="aff2"><addr-line>Department of Breast Surgery, Leeds General Infirmary, Leeds, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Dodwell, D D" sort="Dodwell, D D" uniqKey="Dodwell D" first="D D" last="Dodwell">D D Dodwell</name><affiliation><nlm:aff id="aff3"><addr-line>St James’s Institute of Oncology, St James Hospital, Leeds, UK</addr-line></nlm:aff></affiliation></author><author><name sortKey="Smith, L" sort="Smith, L" uniqKey="Smith L" first="L" last="Smith">L. Smith</name><affiliation><nlm:aff id="aff1"><addr-line>Section of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Leeds University, Leeds, UK</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">The British Journal of Radiology</title><idno type="ISSN">0007-1285</idno><idno type="eISSN">1748-880X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Radiotherapy (RT) is of critical importance in the locoregional management of early breast cancer. Over 50% of patients receive RT at some time during the treatment of their disease, equating to over 500 000 patients worldwide receiving RT each year. Unfortunately, not all patients derive therapeutic benefit and some breast cancers are resistant to treatment, as evidenced by distant metastatic spread and local recurrence. Prediction of individual responses to RT may allow a stratified approach to this treatment permitting those patients with radioresistant tumours to receive higher doses of RT (total and/or tumour cavity boost doses) and/or radiosensitising agents to optimise treatment. Also, for those patients unlikely to respond at all, it would prevent harmful side effects occurring for no therapeutic gain. More selective targeting would better direct National Health Service resources, ease the burden on heavily used treatment RT machines and reduce the economic cost of cancer treatment. Unfortunately, there are no robust and validated biomarkers for predicting RT outcome. We review the available literature to determine whether classification of breast cancers according to their molecular profile may be used to predict successful response to, or increased morbidity from, RT. Class-specific biomarkers for targeting by radiosensitising agents are also discussed.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Radiol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Radiol</journal-id><journal-id journal-id-type="hwp">bjradio</journal-id><journal-id journal-id-type="publisher-id">bjr</journal-id><journal-title-group><journal-title>The British Journal of Radiology</journal-title></journal-title-group><issn pub-type="ppub">0007-1285</issn><issn pub-type="epub">1748-880X</issn><publisher><publisher-name>The British Institute of Radiology.</publisher-name><publisher-loc>48–50 St John Street, London EC1M 4DG, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23392193</article-id><article-id pub-id-type="pmc">3608055</article-id><article-id pub-id-type="publisher-id">bjr12601</article-id><article-id pub-id-type="doi">10.1259/bjr.20120601</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Breast cancer subtypes: response to radiotherapy and potential radiosensitisation</article-title><alt-title alt-title-type="left-running-head">F E Langlands, K Horgan, D D Dodwell et al</alt-title><alt-title alt-title-type="right-running-head">Breast cancer subtypes and response to radiotherapy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Langlands</surname><given-names>F E</given-names></name><degrees>MD, MRCS</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Horgan</surname><given-names>K</given-names></name><degrees>MD, FRCS</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dodwell</surname><given-names>D D</given-names></name><degrees>MD, FRCR</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Smith</surname><given-names>L</given-names></name><degrees>BSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><addr-line>Section of Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, Leeds University, Leeds, UK</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Breast Surgery, Leeds General Infirmary, Leeds, UK</addr-line></aff><aff id="aff3"><label>3</label><addr-line>St James’s Institute of Oncology, St James Hospital, Leeds, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to: Dr Laura Smith E-mail: <email>medlsmi@leeds.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2013</year></pub-date><volume>86</volume><issue>1023</issue><elocation-id>20120601</elocation-id><history><date date-type="received"><day>21</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 The Authors</copyright-statement><copyright-year>2013</copyright-year></permissions><abstract><p>Radiotherapy (RT) is of critical importance in the locoregional management of early breast cancer. Over 50% of patients receive RT at some time during the treatment of their disease, equating to over 500 000 patients worldwide receiving RT each year. Unfortunately, not all patients derive therapeutic benefit and some breast cancers are resistant to treatment, as evidenced by distant metastatic spread and local recurrence. Prediction of individual responses to RT may allow a stratified approach to this treatment permitting those patients with radioresistant tumours to receive higher doses of RT (total and/or tumour cavity boost doses) and/or radiosensitising agents to optimise treatment. Also, for those patients unlikely to respond at all, it would prevent harmful side effects occurring for no therapeutic gain. More selective targeting would better direct National Health Service resources, ease the burden on heavily used treatment RT machines and reduce the economic cost of cancer treatment. Unfortunately, there are no robust and validated biomarkers for predicting RT outcome. We review the available literature to determine whether classification of breast cancers according to their molecular profile may be used to predict successful response to, or increased morbidity from, RT. Class-specific biomarkers for targeting by radiosensitising agents are also discussed.</p></abstract><counts><fig-count count="0"></fig-count><ref-count count="56"></ref-count><page-count count="0"></page-count></counts></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004774 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 004774 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |